Oral-specific chemical carcinogenesis in mice: An exciting model for cancer prevention and therapy

Cancer Prevention Research

Volumn 2, Issue 1, 2009, Pages 10-13

  Wong, Kwong Kwok ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ALPHA TOCOPHEROL SUCCINATE; ANTINEOPLASTIC AGENT; BUDESONIDE; CURCUMIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; GENISTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RAS PROTEIN; RESVERATROL; CARCINOGEN;

ANIMAL MODEL; BRONCHUS DISEASE; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER PREVENTION; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; DRUG TARGETING; DYSPLASIA; ENDOMETRIUM HYPERPLASIA; ENZYME INHIBITION; GENE MUTATION; GENETIC ASSOCIATION; HEAD AND NECK CARCINOMA; HUMAN; INTESTINE TUMOR; LUNG CANCER; MOUTH CANCER; NONHUMAN; ONCOGENE RAS; PRECANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; MOUSE; NEOPLASM; NOTE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENS; DISEASE MODELS, ANIMAL; HUMANS; MICE; NEOPLASMS;

EID: 62349109429     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0234     Document Type: Review

References (34)

1. Czerninski R, Amornphimoltham P, Patel V, Molinolo AA, Gutkind JS. Targeting mTOR by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res 2009;2:27-36.
2. Fenton JI, Hord NG. Stage matters: choosing relevant model systems to address hypotheses in diet and cancer chemoprevention research. Carcinogenesis 2006;27:893-902.
3. Wu W, Celestino J, Milam MR, et al. Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor γ agonist rosiglitazone in the PTEN heterozygote murine model. Int J Gynecol Cancer 2008;18:329-338
4. Khor TO, Cheung WK, Prawan A, Reddy BS, Kong AN. Chemoprevention of familial adenomatous polyposis in Apc(Min/+) mice by phenethyl isothiocyanate (PEITC). Mol Carcinog 2008;47:321-325
5. Tyagi A, Raina K, Singh RP, et al. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 2007;6:3248-3255
6. Granville CA, Warfel N, Tsurutani J, et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 2007;13:2281-2289 (Pubitemid 46649898)
7. Bhutani M, Pathak AK, Fan Y-H, et al. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res 2008;1:39-44.
8. Squarize CH, Castilho RM, Gutkind JS. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res 2008;68:7066-7072
9. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007;13:4964-4973 (Pubitemid 47502060)
10. Moral M, Paramio JM. Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 2008;23:1269-1278
11. Kamata N, Chida K, Rikimaru K, Horikoshi M, Enomoto S, Kuroki T. Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture. Cancer Res 1986;46:1648-1653 (Pubitemid 16121484)
12. Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-248 (Pubitemid 40194293)
13. Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005;5:127-135
14. Shimizu S, Seki N, Sugimoto T, et al. Identification of molecular targets in head and neck squamous cell carcinomas based on genome-wide gene expression profiling. Oncol Rep 2007;18:1489-1497
15. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004;5:311-316
16. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-913 (Pubitemid 40559004)
17. Lorberg A, Hall MN. TOR: the first 10 years. Curr Top Microbiol Immunol 2004;279:1-18.
18. Kopelovich L, Fay JR, Sigman CC, Crowell JA. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2007;16:1330-1340 (Pubitemid 47076862)
19. Zhang X, Jin B, Huang C. The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets 2007;7:305-316 (Pubitemid 46849235)
20. Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007;6:2139-2148 (Pubitemid 47294742)
21. Wang Z. The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors. Curr Pharm Des 2005;11:1771-1777 (Pubitemid 40668135)
22. Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005;4:1448-1455
23. Bacus SS, Altomare DA, Lyass L, et al. AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 2002;21:3532-3540 (Pubitemid 34587685)
24. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62:5645-5650
25. Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000;21:179-182
26. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997;57:5489-5492
27. Lam S, leRiche JC, McWilliams A, et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004;10:6502-6511
28. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-780
29. Wang D, Veena MS, Stevenson K, et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor {κ}B by an AKT-independent pathway. Clin Cancer Res 2008;14:6228-6236
30. Gu X, Song X, Dong Y, et al. Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2008;14:1840-1848
31. Lu SL, Herrington H, Reh D, et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006;20:1331-1342 (Pubitemid 43727593)
32. Caulin C, Nguyen T, Longley MA, Zhou Z, Wang XJ, Roop DR. Inducible activation of oncogenic K-ras results in tumor formation in the oral cavity. Cancer Res 2004;64:5054-5058 (Pubitemid 39006517)
33. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Cur Protoc Hum Genet 2008;Chapter 10: Unit 10-11.
34. Mayburd AL, Martlinez A, Sackett D, et al. Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886. Clin Cancer Res 2006;12:1820-1827